Jeff Yass’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-149,800
| Closed | -$1.11M | – | 14024 |
|
|
2026
Q1 | $1.11M | Buy |
149,800
+31,100
| +26% | +$202K | ﹤0.01% | 7602 |
|
|
2025
Q4 | $747K | Buy |
+118,700
| New | +$692K | ﹤0.01% | 7873 |
|
|
2025
Q2 | – | Sell |
-11,800
| Closed | -$57.6K | – | 13250 |
|
|
2025
Q1 | $57.6K | Sell |
11,800
-400
| -3% | -$2.43K | ﹤0.01% | 11811 |
|
|
2024
Q4 | $82K | Buy |
+12,200
| New | +$90.9K | ﹤0.01% | 11459 |
|
|
2024
Q1 | – | Sell |
-7,880
| Closed | -$74.9K | – | 12801 |
|
|
2023
Q4 | $74.9K | Hold |
7,880
| – | – | ﹤0.01% | 11518 |
|
|
2023
Q3 | $93.8K | Sell |
7,880
-20
| -0.3% | -$354 | ﹤0.01% | 10973 |
|
|
2023
Q2 | $194K | Hold |
7,900
| – | – | ﹤0.01% | 10304 |
|
|
2023
Q1 | $247K | Sell |
7,900
-960
| -11% | -$55.5K | ﹤0.01% | 10143 |
|
|
2022
Q4 | $624K | Buy |
8,860
+5,120
| +137% | +$380K | ﹤0.01% | 7301 |
|
|
2022
Q3 | $322K | Sell |
3,740
-17,580
| -82% | -$1.71M | ﹤0.01% | 9615 |
|
|
2022
Q2 | $1.76M | Buy |
21,320
+3,970
| +23% | +$350K | ﹤0.01% | 5180 |
|
|
2022
Q1 | $2.88M | Buy |
17,350
+13,240
| +322% | +$1.9M | ﹤0.01% | 4701 |
|
|
2021
Q4 | $687K | Buy |
+4,110
| New | +$464K | ﹤0.01% | 8315 |
|
|
2020
Q3 | – | Sell |
-7,690
| Closed | -$398K | – | 10867 |
|
|
2020
Q2 | $398K | Buy |
+7,690
| New | +$388K | ﹤0.01% | 7827 |
|
Jeff Yass's KZR Position: Q4 2024 in Review
Jeff Yass sold out of Kezar Life Sciences (KZR) in Q4 2024, closing a stake of 1,259 shares — an estimated $9.38K sold.
Jeff Yass first reported a position in KZR in Q1 2020 and held it in 16 quarters. The position peaked at $1.1M in Q1 2022. 43 funds tracked by Wall St. Rank hold KZR as of Q4 2024.
- Jeff Yass reported no remaining Kezar Life Sciences position as of Q4 2024 after selling out during the quarter.
- Jeff Yass sold 1,259 Kezar Life Sciences shares in Q4 2024, an estimated $9.38K.
- Jeff Yass first reported a position in Kezar Life Sciences in Q1 2020 and held it in 16 quarters.
- Jeff Yass's Kezar Life Sciences position peaked at $1.1M in Q1 2022.
- 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2024.
Based on Susquehanna International Group's 13F filing for Q4 2024, filed 14 Feb 2025.